liver cancer
Conditions
Interventions
Control Group:Lenvatinib mesilate (National Drug Approval No. HJ20200044) 8 mg, qd, orally, combined with sintilimab injection (National Drug Approval No. S20180016) 200 mg IV infusion, every 3 weeks.
Experimental group:In addition to Western medical treatment, take the modified Si Ni Decoction granules (self-made granules by Suzhou Traditional Chinese Medicine Hospital, composed of 10g processed a
Sponsors
Suzhou City Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients who meet the diagnostic criteria of Western medicine and the criteria of syndrome differentiation in traditional Chinese medicine, aged between 18 and 75 years old; 2) At least one measurable lesion; 3) Karnofsky Performance Status (KPS) score of 60 or higher; 4) Expected survival of more than 3 months; 5) Normal results in routine blood tests, biochemical functions, and no severe impairment of heart or lung functions; 6) Child-Pugh class A or well-compensated class B (=7 points); 7) Voluntary participation in the trial, no severe drug allergies, and good compliance.
Exclusion criteria
Exclusion criteria: 1) Patients with incomplete medical documentation; 2) Patients with concurrent solid tumors or hematologic malignancies; 3) Individuals with severe systemic infections, myelosuppression, or severe cardiovascular or cerebrovascular diseases; 4) Lactating or pregnant women; 5) Patients with severe mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine Syndrome Score;Quality of Life Rating;Objective Response Rate; | — |
Countries
China
Contacts
Public ContactJingdong Gao
Affiliated Suzhou City Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine
Outcome results
None listed